

Gene Therapy

Part I: Technologies & Markets

by

Prof. K. K. Jain
MD, FRACS, FFPM
Jain PharmaBiotech
Basel, Switzerland

November 2018

A Jain PharmaBiotech Report

A U T H O R ' S B I O G R A P H Y

Professor K. K. Jain is a neurologist/neurosurgeon by training and has been working in the biotechnology/biopharmaceuticals industry for several years. He received graduate training in both Europe and US, has held academic positions in several countries, and is a Fellow of the Faculty of Pharmaceutical Medicine of the Royal College of Physicians of UK. Currently, he is a consultant at Jain PharmaBiotech. Prof. Jain's 478 publications include 30 books (6 as editor + 24 as author) and 50 special reports, which have covered important areas in biotechnology, gene therapy and biopharmaceuticals.

Prof. Jain has edited "Drug Delivery Systems" (1st edn 2008, 2nd edn 2014, 3rd edn 2019, in preparation) and "Drug Delivery to the Central Nervous System" (2010), both published by Humana/Springer. His other recent books include "Handbook of Nanomedicine" (Springer 2008; Chinese edition, Peking University Press 2011; 3rd ed Springer 2017), "Textbook of Personalized Medicine" (Springer 2009; Japanese ed 2012; 2nd ed Springer, 2015), "Handbook of Biomarkers" (Springer 2010; Chinese edition. Chemical Industry Press 2016, 2nd ed Springer 2017) and "Handbook of Neuroprotection" (Springer 2011, 2nd edn 2019 in preparation). Books that contain chapters on gene therapy include: Applications of Biotechnology in Cardiovascular Therapeutics (Springer 2011), Applications of Biotechnology in Neurology (Springer 2013), and Applications of Biotechnology in Oncology (Springer 2014). He has also edited "Applied Neurogenomics" (Springer in 2015).

A B O U T T H I S R E P O R T

Prof. Jain wrote the first commercial report on Gene Therapy in 1995, which was published by PJB Publication, London. This was followed by reports on Gene Therapy Vectors and Cancer Gene Therapy (1996). A report on Gene Therapy of 10 was published by Decision Resources in 1997. In 1998, Prof. Jain wrote a Textbook of Gene Therapy, which was the first book on this subject to be translated into the Chinese language in 2000. A book on gene therapy companies was published in 2000 by John Wiley & Sons and continued to be updated online at Wiley's web site until 2003. In 2004, when the copyright reverted to Prof. Jain, it became part II of the Gene Therapy report. This report supercedes and updates all the previous books as well as reports.

November 2018
Copyright © 2018 by

Jain PharmaBiotech
Bläsiring 7
CH-4057 Basel
Switzerland

Tel & Fax: **+4161-6924461**
Email: **info@pharmabiotech.ch**
Web site: **http://pharmabiotech.ch/**

All rights reserved. No part of this publication may be reproduced, stored in a retrieval system, or transmitted in any form or by any means, electronic, mechanical, photocopying, or otherwise without the prior written permission of the Publisher. This report may not be lent, resold or otherwise traded in any manner without the consent of the Publisher. While all reasonable steps have been taken to ensure the accuracy of the information presented, the Publisher cannot accept responsibility for inadvertent errors or omissions.

TABLE OF CONTENTS

0. Executive Summary	21
1. Introduction	23
Definitions	23
Historical evolution of gene therapy	23
Relation of gene therapy to other biotechnologies.....	25
Molecular biological basics for gene therapy	26
Genome.....	26
DNA	27
RNA	27
<i>Alternative RNA splicing.....</i>	<i>28</i>
Genes.....	29
<i>Silent gene mutations.....</i>	<i>29</i>
Gene regulation	29
Gene expression	30
ENCODE	31
Chromosomes	32
Telomeres.....	32
Mitochondria	33
Proteins	34
2. Gene Therapy Technologies	35
Classification of gene therapy techniques.....	35
Ex vivo and in vivo gene therapy	36
Ex vivo gene therapy.....	36
In vivo gene therapy	37
Physical methods of gene transfer.....	37
Electroporation	37
Applications of electroporation	38
<i>Clinical applications of electroporation</i>	<i>39</i>
<i>Advantages of electroporation</i>	<i>40</i>
<i>Limitations of electroporation</i>	<i>40</i>
Hydrodynamic	40
Microinjection.....	41
Particle bombardment	41
Ultrasound-mediated transfection	43
Molecular vibration.....	44
Application of pulsed magnetic field and superparamagnetic nanoparticles	44
Gene transfection using laser irradiation	44
Photochemical transfection.....	45
Chemical methods of gene transfer	45
Gene repair and replacement.....	45
Gene repair by single-stranded oligonucleotides.....	46
History and current status of chimeraplasty	46
Genome editing.....	46
Gene editing by zinc finger nucleases.	46
Gene editing by using short synthetic oligonucleotides.....	47
Genome engineering by using TALENs	47
Genome editing by homologous recombination	47
Gene editing by homing endonucleases	47
Genome editing by using CRISPR system	48
<i>A method for generating genome-wide gRNA libraries for CRISPR</i>	<i>49</i>
<i>CRISPR-genome organization system</i>	<i>49</i>
<i>CRISPR vs other gene editing tools</i>	<i>50</i>
<i>CRISPR-FRT</i>	<i>50</i>
<i>CRISPR for studying human embryogenesis</i>	<i>51</i>
<i>CRISPER system for creating animal models of human diseases.....</i>	<i>51</i>
<i>CRISPR/Cas9 technology for drug discovery</i>	<i>51</i>
<i>Expanding the range of Cas9s</i>	<i>52</i>
<i>Inducible CRISPR/Cas9 for multiple gene targeting</i>	<i>52</i>
<i>Photoactivatable CRISPR-Cas9.....</i>	<i>52</i>
<i>Protein delivery and genome editing.....</i>	<i>53</i>
Potential clinical applications of CRISPR systems.....	53
<i>Autosomal dominant retinitis pigmentosa.....</i>	<i>54</i>
<i>Correction of a gene mutation in the human embryo</i>	<i>54</i>
<i>Glaucoma</i>	<i>55</i>
<i>PERV blockage by CRISPR to facilitate xenotransplantation</i>	<i>55</i>

<i>RNA editing with CRISPR</i>	55
<i>Use of CRISPR for β-hemoglobinopathies</i>	56
<i>Use of CRISPR to restore hereditary hearing loss</i>	56
<i>Clinical trial of CRISPR in human cancer</i>	58
<i>Complications and limitations of CRISPR/Cas9 technology</i>	58
<i>Companies developing CRISPR technology</i>	59
Clinical studies of gene editing.....	59
Targeted genome editing by artificial nucleases.....	60
Future gene editing tools.....	60
Comparison of gene editing with techniques for suppression of gene mutations.....	60
Base editing of the genome	62
Base editing by protein engineering.....	62
Adenine base editors for genomic DNA.....	62
mRNA gene therapy	63
Spliceosome mediated RNA trans-splicing.....	63
Vectors for gene therapy	63
Basic considerations.....	63
Use of genes as pharmaceuticals.....	64
The ideal vector for gene therapy.....	64
Viral vectors.....	65
<i>Adenovirus vectors</i>	65
<i>Adeno-associated virus vectors</i>	67
<i>Alphavirus vectors</i>	70
<i>Baculovirus vectors</i>	71
<i>Foamy virus vectors</i>	71
<i>Herpes simplex virus vectors</i>	71
<i>Lentiviral vectors</i>	74
<i>Multicistronic retroviral vectors</i>	75
<i>Retroviral vectors</i>	75
<i>Oncogenic potential of retroviral vectors</i>	77
<i>Quantification of viral vectors</i>	77
<i>Future of viral vectors</i>	77
<i>Companies using viral vectors</i>	78
Nonviral vectors for gene therapy.....	79
<i>Anionic lipid-DNA complexes</i>	80
<i>Cationic lipid-DNA complexes</i>	80
<i>Effects of shape of DNA molecules on delivery with nonviral vectors</i>	80
<i>Electrostatic modifications of surface to improve gene delivery</i>	81
<i>Liposomes for gene therapy</i>	81
<i>Liposome-nucleic acid complexes</i>	83
<i>Liposome-HVJ complex</i>	83
<i>Transposons DNA vectors</i>	83
<i>Polycation-DNA complexes (polyplexes)</i>	84
<i>Plasmid DNA vs minicircle DNA</i>	85
<i>Polymer vectors for gene therapy</i>	86
<i>Synthetic biology and DNA vectors</i>	86
<i>Synthetic peptide complexes</i>	87
<i>Future of nonviral vs viral vectors</i>	87
Nanobiotechnology for gene therapy.....	87
<i>Antisense nanoparticles</i>	88
<i>Dendrimers</i>	88
<i>Cochleates</i>	88
<i>Calcium phosphate nanoparticles as nonviral vectors</i>	89
<i>DNA nanoparticles as nonviral vectors</i>	89
<i>Gelatin nanoparticles for gene delivery</i>	89
<i>Lipid nanoparticles for nucleic acid delivery</i>	89
<i>Lipid nanoparticles for delivery of genome-editing proteins</i>	90
<i>Nanoparticles as nonviral vectors for gene therapy</i>	90
<i>Nanoparticles with virus-like function as gene therapy vectors</i>	91
<i>Nanobiologics for nucleic acid delivery</i>	91
<i>Nonionic polymeric micelles for oral gene delivery</i>	91
<i>Silica nanoparticles as a nonviral vector for gene delivery</i>	92
<i>Virus-like particles as nonviral vector</i>	92
Receptor-mediated endocytosis.....	92
Artificial viral vectors.....	93
Directed evolution of AAV to create efficient gene delivery vectors.....	94
Bacterial ghosts as DNA delivery systems.....	94
Bacteria plus nanoparticles for gene delivery into cells.....	94
Chromosome-based vectors for gene therapy.....	95
<i>Mammalian artificial chromosomes (MACs)</i>	96
<i>Human artificial chromosomes (HACs)</i>	96

<i>ΦC31 integrase system</i>	97
Companies using nonviral vectors	97
Concluding remarks about vectors	98
Cell-mediated gene therapy	99
Fibroblasts	99
Skeletal muscle cells	100
Vascular smooth muscle cells	100
Keratinocytes	101
Hepatocytes.....	101
Lymphocytes.....	101
<i>Regulating protein delivery by genetically encoded lymphocytes</i>	101
Implantation of microencapsulated genetically modified cells	102
Stem cell gene therapy	102
<i>Combination of gene therapy with therapeutic cloning</i>	103
<i>Expansion of transduced HSCs in vivo</i>	103
<i>Gene delivery to stem cells by artificial chromosome expression</i>	103
<i>Improving delivery of genes to stem cells</i>	104
<i>In utero gene therapy using stem cells</i>	104
<i>Lentiviral vectors for gene transfer to marrow stem cells</i>	104
<i>Linker based sperm-mediated gene transfer technology</i>	104
<i>Mesenchymal stem cells for gene therapy</i>	105
<i>Microporation for transfection of MSCs</i>	105
<i>Therapeutic applications for hematopoietic stem cell gene transfer</i>	105
<i>Transdermal gene therapy for drug addiction</i>	105
<i>The future of hematopoietic stem cell gene therapy</i>	106
Role of genetically modified bacteria in gene therapy	106
Routes of administration for gene therapy	107
Direct injection of naked DNA	107
Intramuscular injection.....	108
Intravenous DNA injection	108
Intraarterial delivery	108
Companies with gene delivery devices/technologies	108
Targeted gene therapy	109
Targeted integration.....	110
Bacteriophage integrase system for site-specific gene delivery	110
Controlled-release delivery of DNA	110
Controlled gene therapy	111
Controlled delivery of genetic material.....	111
Controlled induction of gene expression	111
Drug-inducible systems for control of gene expression.....	112
Timed activation of gene therapy by a circuit based on signaling network	113
Small molecules for post-transcriptional regulation of gene expression	113
Light Activated Gene Therapy.....	113
Spatial control of gene expression via local hyperthermia.....	113
Companies with regulated /targeted gene therapy	114
Gene marking	115
Germline gene therapy	115
Potential applications of human germline genome modification	115
Pros and cons of human germline genome modification	116
Role of gene transfer in antibody therapy	117
Genetically engineered vaccines	117
DNA vaccines	118
<i>DNA inoculation technology</i>	118
<i>Methods for enhancing the potency of DNA vaccines</i>	119
<i>Advantages of DNA vaccines</i>	119
Vaccine vectors	119
Challenges and limitations of genetically engineered vaccines.....	120
RNA vaccines.....	121
<i>Nonviral delivery of self-amplifying RNA vaccine</i>	121
Vaccines based on reverse genetics.....	121
Technologies for gene suppression	121
Antisense oligonucleotides	122
Transcription factor decoys	122
Aptamers.....	123
Ribozymes	123
Peptide nucleic acid.....	123
<i>Intracellular delivery of PNAs</i>	124
Locked nucleic acid	124
<i>Zorro-LNA</i>	124
Gene silencing	125
Post-transcriptional gene silencing	125

Definitions and terminology of RNAi	125
RNAi mechanisms	125
Inhibition of gene expression by antigenic RNA	127
RNAi gene therapy	128
microRNA gene therapy	128
Viral vectors for RNAi and miRNA gene therapy	128
Application of molecular diagnostic methods in gene therapy	129
Use of PCR to study biodistribution of gene therapy vector	130
PCR for verification of the transcription of DNA	130
In situ PCR for direct quantification of gene transfer into cells	130
Detection of retroviruses by reverse transcriptase (RT)-PCR.....	130
Confirmation of viral vector integration	131
Monitoring of gene expression	131
<i>Monitoring of gene expression by green fluorescent protein.....</i>	<i>131</i>
<i>Monitoring in vivo gene expression by molecular imaging.....</i>	<i>131</i>
<i>Advantages of gene therapy compared with protein therapy.....</i>	<i>132</i>
Formulation, transport and storage of materials for gene therapy	132
3. Clinical Applications of Gene Therapy	133
Introduction	133
Aging research.....	133
Bone and joint disorders.....	133
Bone fractures.....	133
Gene therapy for intervertebral disc degeneration	134
Spinal fusion	135
Osteogenesis imperfecta	135
Rheumatoid arthritis.....	136
<i>Local or systemic treatment</i>	<i>136</i>
<i>In vivo or ex vivo gene therapy of RA.....</i>	<i>136</i>
<i>Clinical trials of gene therapy for rheumatoid arthritis.....</i>	<i>137</i>
Gene therapy for osteoarthritis.....	138
<i>Gene therapy strategies for osteoarthritis</i>	<i>138</i>
<i>Clinical trials of gene therapy for osteoarthritis</i>	<i>140</i>
Sports injuries.....	140
<i>Repair of articular cartilage defects</i>	<i>140</i>
Regeneration and replacement of bone by gene therapy	141
Bacterial infections	142
Antisense approach to bacterial infections	142
Dentistry.....	142
Tissue engineering in dental implant defects	142
Endocrine and metabolic disorders	143
Introduction	143
Gene therapy of obesity.....	143
<i>AAV vector-mediated delivery of GDNF for obesity</i>	<i>143</i>
<i>Oligopeptide for targeted nonviral gene delivery to adipocytes.....</i>	<i>144</i>
<i>Viral vector-mediated leptin gene therapy.....</i>	<i>144</i>
Diabetes mellitus	145
Methods of gene therapy of diabetes mellitus	145
<i>Viral vector-mediated gene transfer in diabetes</i>	<i>146</i>
<i>Endogenous reprogramming of α cells into β cells</i>	<i>147</i>
<i>Gene delivery with ultrasonic microbubble destruction technology.....</i>	<i>147</i>
<i>Genetically engineered cells for diabetes mellitus</i>	<i>147</i>
<i>Genetically altered liver cells</i>	<i>147</i>
<i>Genetically modified stem cells</i>	<i>148</i>
<i>Genetically engineered dendritic cells</i>	<i>148</i>
<i>Glucokinase and insulin co-expression</i>	<i>148</i>
<i>Leptin gene therapy</i>	<i>149</i>
<i>Concluding remarks about cell and gene therapy of diabetes</i>	<i>149</i>
Gene therapy of growth-hormone deficiency	150
Gastrointestinal disorders.....	150
Introduction	150
Methods of gene transfer to the gastrointestinal tract.....	151
<i>Direct delivery of genes</i>	<i>151</i>
<i>Naked plasmid DNA into the submucosa</i>	<i>151</i>
<i>Viral vectors.....</i>	<i>151</i>
<i>Receptor-mediated endocytosis</i>	<i>151</i>
Indications for gastrointestinal gene therapy	152
<i>Gene therapy for inflammatory disorders of the bowel.....</i>	<i>152</i>
Gene transfer to the salivary glands	153
<i>Potential clinical applications of salivary gene therapy</i>	<i>153</i>
Hematology	154

Hemophilias	154
<i>Gene therapy of hemophilia</i>	154
<i>Hemophilia A</i>	155
<i>Hemophilia B</i>	156
<i>Concluding remarks about gene therapy of hemophilias</i>	158
Hemoglobinopathies.....	159
<i>Gene therapy for β-thalassemia</i>	159
<i>Gene therapy for sickle cell disease</i>	161
<i>Gene therapy and RNAi for SCD based on stem cells</i>	161
<i>Gene editing in sickle cell disease</i>	162
<i>Gene editing using ZFN as treatment for both SCD and β-thalassemia</i>	162
<i>Gene editing using CRISPR-Cas9 for both SCD and β-thalassemia</i>	162
<i>Gene therapy of Fanconi's anemia</i>	163
Acquired hematopoietic disorders.....	163
<i>Chronic acquired anemias</i>	163
<i>Neutropenia</i>	164
<i>Thrombocytopenia</i>	165
Concluding remarks about gene therapy of hemoglobinopathies.....	165
Companies involved in gene therapy of hematological disorders.....	166
In utero/fetal gene therapy.....	166
Fetal gene transfer techniques.....	166
Animal models of fetal gene therapy.....	167
Potential applications of fetal gene therapy.....	167
<i>Fetal gene therapy for cystic fibrosis</i>	168
<i>Fetal intestinal gene therapy</i>	168
<i>Gene therapy for fetal growth restriction</i>	169
Hearing disorders.....	169
Potential of gene therapy.....	169
Vectors for gene therapy of hearing disorders.....	170
Auditory hair cell replacement and hearing improvement by gene therapy.....	170
Kidney diseases.....	171
End-stage renal disease.....	171
Methods of gene delivery to the kidney.....	171
<i>Gene transfer into kidney by adenoviral vectors</i>	172
<i>Non-viral gene transfer to the kidneys</i>	172
<i>Gene transfer into the glomerulus by HVJ-liposome</i>	172
<i>Bone marrow stem cells for renal disease</i>	172
<i>Mesangial cell therapy</i>	173
<i>Liposome-mediated gene transfer into the tubules</i>	173
<i>Gene transfer to tubules with cationic polymer polyethylenimine</i>	173
Gene therapy in animal experimental models of renal disease.....	174
Genetic manipulations of the embryonic kidney.....	174
Antisense intervention in glomerulonephritis.....	175
Gene therapy for renal fibrosis.....	175
Use of genetically engineered cells for uremia due to renal failure.....	175
Concluding remarks.....	176
Liver disorders.....	176
Techniques of gene delivery to liver.....	177
<i>Direct injection of DNA into liver</i>	177
<i>Local gene delivery by isolated organ perfusion</i>	177
<i>Liposome-mediated direct gene transfer</i>	177
<i>Retroviral vector for gene transfer to liver</i>	178
<i>Adenoviral vectors for gene transfer to liver</i>	178
<i>Receptor-mediated approach</i>	178
Cell therapy for liver disorders.....	178
<i>Transplantation of genetically modified hepatocytes</i>	179
<i>Genetically modified hematopoietic stem cells</i>	179
<i>Gene therapy by ex vivo transduced liver progenitor cells</i>	179
Gene therapy of genetic diseases affecting the liver.....	180
<i>Crigler-Najjar syndrome</i>	180
<i>Hereditary tyrosinemia type I (HT1)</i>	180
<i>Hereditary tyrosinemia type 3</i>	181
Gene therapy of acquired diseases affecting the liver.....	181
<i>Cirrhosis of liver</i>	181
Ophthalmic disorders.....	181
Introduction to gene therapy of ophthalmic disorders.....	181
Methods of gene therapy for ophthalmic disorders.....	182
<i>Delivery of gene therapy by intravitreal injection</i>	183
<i>DNA nanoparticles for nonviral gene transfer to the eye</i>	184
<i>Optogenetic gene therapy for blindness due to retinal degeneration</i>	184
Age-related macular degeneration.....	185

Inherited disorders of optic nerve affecting vision	186
<i>Leber hereditary optic neuropathy</i>	186
<i>Gene therapy for LHON</i>	187
Inherited retinal degenerations.....	187
<i>Choroideremia</i>	188
<i>Leber congenital amaurosis</i>	189
<i>Retinitis pigmentosa</i>	191
<i>Stargardt disease</i>	192
Other inherited disorders affecting vision	192
<i>Color blindness</i>	192
<i>Usher syndrome</i>	193
<i>X-linked retinoschisis</i>	194
Diabetic retinopathy	195
Future of gene therapy of inherited retinal degenerations	195
<i>Combining cell and gene therapies for retinal disorders</i>	195
Prevention of complications associated with eye surgery	196
<i>Prevention of proliferative retinopathy by gene therapy</i>	196
<i>Posterior capsule opacification after cataract surgery</i>	196
Autoimmune uveitis	196
Retinal ischemic injury.....	196
Corneal disorders.....	197
Glaucoma	197
Corneal scarring	198
Companies developing gene therapy for eye disorders.....	198
Organ transplantation.....	198
Introduction	198
DNA vaccines for transplantation	199
Gene therapy for prolonging allograft survival	199
<i>Genetically modified Tregs expressing CAR for preventing GVHD</i>	199
Gene therapy in lung transplantation.....	200
Role of gene therapy in liver transplantation	200
Gene therapy in kidney transplantation.....	200
Veto cells and transplant tolerance.....	201
Pulmonary disorders.....	201
Techniques of gene delivery to the lungs	201
<i>Adenoviral vectors</i>	202
<i>Nonviral vectors</i>	203
<i>Aerosolization as an aid to gene transfer to lungs</i>	203
Cystic fibrosis.....	203
<i>Genetics and clinical features</i>	203
<i>Gene therapy for CF</i>	204
<i>CFTR gene transfer in CF</i>	204
<i>Concluding remarks about gene therapy of CF</i>	205
Miscellaneous pulmonary disorders	206
<i>Gene therapy for pulmonary arterial hypertension</i>	206
<i>Gene therapy for bleomycin-induced pulmonary fibrosis</i>	207
<i>Gene therapy of emphysema due to α1-antitrypsin deficiency</i>	207
<i>Gene therapy for asthma</i>	207
<i>Gene therapy for adult respiratory distress syndrome</i>	208
<i>Gene therapy for lung injury</i>	208
<i>Gene therapy for bronchopulmonary dysplasia</i>	208
Concluding remarks about gene therapy of lungs.....	209
Companies involved in pulmonary gene therapy	209
Skin and soft tissue disorders.....	210
Gene transfer to the skin	210
<i>Electroporation for transdermal delivery of plasmid DNA</i>	210
<i>Electroporation for transdermal delivery of DNA vaccines</i>	211
<i>Liposomes for transdermal gene delivery</i>	211
<i>Ultrasound and topical gene therapy</i>	211
Gene therapy in skin disorders	211
<i>Gene therapy of hair loss</i>	212
<i>Gene therapy for epidermolysis bullosa</i>	212
<i>Gene therapy for xeroderma pigmentosa</i>	214
<i>Gene therapy for lamellar ichthyosis</i>	214
Gene transfer techniques for wound healing	214
Urogenital disorders	215
Gene therapy for urinary tract dysfunction	215
Gene therapy for erectile dysfunction	215
<i>NOS gene transfer for erectile dysfunction</i>	215
<i>Clinical trial of hMaxi-K Gene transfer in erectile dysfunction</i>	216
<i>Gene therapy for erectile dysfunction due to nerve injury</i>	216

<i>Concluding remarks on gene therapy for erectile dysfunction</i>	216
Veterinary gene therapy	216
Gene therapy for mucopolysaccharidosis VII in dogs	217
Gene therapy to increase disease resistance.....	217
Gene therapy for infections	217
Gene therapy for chronic anemia	218
Gene therapy for endocrine disorders	218
Gene therapy for arthritis.....	218
Cancer gene therapy	219
<i>Brain tumors in cats and dogs</i>	219
<i>Breast cancer in dogs</i>	219
<i>Canine hemangiosarcoma</i>	220
<i>Canine melanoma</i>	220
<i>Canine soft tissue sarcoma</i>	221
Melanoma in horses	221
4. Gene Therapy of Genetic Disorders	222
Introduction	222
Primary immunodeficiency disorders	223
Severe combined immune deficiency	224
Chronic granulomatous disease	227
Wiskott-Aldrich syndrome	227
Purine nucleoside phosphorylase deficiency	228
Major histocompatibility class II deficiency	228
Future prospects of gene therapy of inherited immunodeficiencies	229
Metabolic disorders	229
Alpha1-antitrypsin deficiency.....	230
<i>AAV mediated gene therapy for α1-antitrypsin deficiency</i>	230
<i>iPSCs for targeted gene correction of α1-antitrypsin deficiency</i>	231
<i>Gene editing for AAT deficiency</i>	232
Adrenoleukodystrophy	233
Canavan disease.....	233
Lesch-Nyhan syndrome	234
Lipoprotein lipase deficiency.....	234
<i>Alipogene tiparvovec</i>	235
Ornithine transcarbamylase deficiency.....	235
<i>Gene therapy for OTCD</i>	236
<i>AAV-mediated gene editing for OTCD using CRISPR-Cas9</i>	236
Phenylketonuria.....	237
Porphyrias	237
Tetrahydrobiopterin deficiency.....	238
Lysosomal storage disorders	238
Batten disease.....	239
Fabry's disease	240
Farber's disease.....	240
Gaucher disease	240
<i>Animals models of Gaucher's disease</i>	241
<i>Gene therapy of Gaucher's disease</i>	241
Hunter syndrome.....	242
Krabbe's disease.....	243
Metachromatic leukodystrophy	243
Mucopolysaccharidosis type 1 (Hurler syndrome)	244
Niemann-Pick type A disease.....	245
Pompe disease	245
Sanfilippo A syndrome.....	246
Sly syndrome	246
Tay-Sachs disease	247
Future prospects of gene therapy of lysosomal storage disorders	247
Trinucleotide repeat disorders	248
Muscular dystrophies	248
Duchenne muscular dystrophy (DMD).....	248
<i>Animal models for gene therapy of DMD</i>	249
<i>Antisense approaches to DMD</i>	249
<i>CRISPR/Cas9 gene editing for DMD</i>	249
<i>Exon-skipping for DMD</i>	250
<i>Galgt2 gene therapy</i>	251
<i>Liposome-mediated gene transfer</i>	251
<i>Microdystrophin gene therapy</i>	252
<i>Myoblast-based gene transfer in DMD</i>	252
<i>Plasmid-mediated gene therapy</i>	252
<i>Purinoreceptor P2RX7 ablation</i>	252

<i>Post-transcriptional modulation of gene expression in DMD</i>	253
<i>Repair/Editing of dystrophin gene</i>	253
<i>Routes of administration of gene therapy in DMD</i>	256
<i>Types of dystrophin constructs</i>	257
<i>Viral vectors for DMD</i>	257
<i>Conclusions and future of gene therapy of DMD</i>	258
Limb-girdle muscular dystrophy	259
Myotonic dystrophy	259
Spinal muscular atrophy	260
<i>Gene therapy for SMA</i>	260
<i>Antisense therapy of SMA</i>	261
<i>Nusinersen</i>	261
<i>Nusinersen vs scAAV9 gene therapy for SMA</i>	262
X-linked myotubular myopathy (XLMTM)	262
Hereditary neuropathies	262
Charcot-Marie-Tooth disease	262
Hereditary axonal neuropathies of the peripheral nerves	263
Gene therapy of mitochondrial disorders	263
Techniques for mitochondrial replacement therapy	264
Status of mitochondrial replacement and transfer therapies	264
Companies involved in gene therapy of genetic disorders	265
5. Gene Therapy of Cancer	268
Strategies for cancer gene therapy	268
Direct gene delivery to the tumor	269
Injection into tumor	269
<i>Direct injection of adenoviral vectors</i>	269
<i>Direct injection of a plasmid DNA-liposome complex</i>	270
<i>A polymer approach to local gene therapy for cancer</i>	270
Electroporation for cancer gene therapy	270
Control of gene expression in tumor by local heat	271
Radiation-guided gene therapy of cancer	271
Radioprotective gene therapy of cancer	271
Nanoparticles to facilitate combination of hyperthermia and gene therapy	272
Immunogene therapy of cancer	272
Cell-based cancer gene therapy	273
Adoptive cell therapy	273
Cytokine gene therapy	274
Genetic modification of human hematopoietic stem cells	276
Cancer vaccines	277
Genetically modified cancer cell vaccines	277
<i>GVAX cancer vaccines</i>	277
<i>Genetically modified dendritic cells</i>	278
Nucleic acid-based cancer vaccines	278
<i>DNA cancer vaccines</i>	278
<i>RNA vaccines</i>	279
Viral vector-based cancer vaccines	279
<i>Intradermal delivery of cancer vaccines by Ad vectors</i>	280
Vaccines based on genetically engineered nonviral vectors	280
Future of cancer vaccines	280
Companies involved in nucleic acid-based cancer vaccines	280
Monoclonal antibody gene transfer for cancer	281
Transfer and expression of intracellular adhesion-1 molecules	282
Other gene therapy techniques for immunotherapy of cancer	282
Chemokines	282
CRISPR for immunogene therapy	283
Engineered viruses as anticancer immunotherapy vectors	283
Fas (Apo-1)	284
Major Histocompatibility Complex (MHC) Class I	284
IGF (Insulin-Like Growth Factor)	284
Cancer immunotherapies targeting multiple mechanisms	284
Inhibition of immunosuppressive function in cancer	285
Delivery of toxic genes to tumor cells for eradication	285
Gene-directed enzyme prodrug therapy	285
Combination of gene therapy with radiotherapy	286
Correction of genetic defects in cancer cells	286
Targeted gene therapy for cancer	286
Antiangiogenic therapy for cancer	287
Bacteria as novel anticancer gene vectors	287
Cancer-specific gene expression	288
Cancer-specific transcription	288

Delivery of retroviral particles hitchhiking on T cells	289
Electrogene and electrochemotherapy	289
Epidermal growth factor-mediated DNA delivery	289
Gene expression in hypoxic tumor cells	289
Genetically modified T cells for targeting tumors	290
<i>Chimeric antigen receptor T cells</i>	290
<i>CAR-T cells targeting both CD19 and CD22</i>	293
<i>Remote control of CAR-T cells</i>	293
Genetically engineered stem cells for targeting tumors	293
Hematopoietic stem cells for targeted cancer gene therapy	294
Immunolipoplex for delivery of p53 gene	294
Nanomagnets for targeted cell-based cancer gene therapy.....	295
Nanoparticles for targeted site-specific delivery of anticancer genes	295
Targeted cancer therapy using a dendrimer-based synthetic vector	296
Tumor-targeted gene therapy by receptor-mediated endocytosis	296
Virus-mediated oncolysis.....	296
Cytokine-induced killer cells for delivery of an oncolytic virus	296
Monitoring of viral-mediated oncolysis by PET	297
Oncolytic adenoviruses	297
Oncolytic HSV.....	298
Oncolytic measles viruses	299
Oncolytic vaccinia virus.....	299
Oncolytic vesicular stomatitis virus.....	300
Targeted cancer treatments based on oncolytic viruses.....	300
Concluding remarks on oncolytic gene therapy	300
<i>Companies developing oncolytic viruses</i>	301
Apoptotic approach to improve cancer gene therapy	302
Tumor suppressor gene therapy	302
P53 gene therapy.....	302
BRIT1 gene therapy	303
Nitric oxide-based cancer gene therapy	303
Anticancer effect of nitric oxide synthase	303
Gene therapy for radiosensitization of cancer	303
Gene therapy of cancer of selected organs	304
Gene therapy for bladder cancer.....	304
Gene therapy for glioblastoma.....	304
<i>Adenoviral vectors for treatment of brain tumors</i>	305
<i>Antiangiogenic gene therapy</i>	306
<i>Autophagy induced by conditionally replicating adenoviruses</i>	306
<i>Baculovirus vector for diphtheria toxin gene therapy</i>	307
<i>Cerepro® (sitimagene ceradenovec)</i>	307
<i>Gene therapy targeting hepatocyte growth factor</i>	307
<i>Genetically engineered MSCs for gene delivery to intracranial gliomas</i>	308
<i>Intravenous gene delivery with nanoparticles into brain tumors</i>	308
<i>Ligand-directed delivery of dsRNA molecules targeted to EGFR</i>	308
<i>Olig2 targeting to hinder growth of treatment-resistant glioblastomas</i>	309
<i>RNAi gene therapy of brain cancer</i>	309
<i>Targeting normal brain cells with an AAV vector encoding interferon-β</i>	309
<i>Viral oncolysis of glioblastoma multiforme</i>	310
Gene therapy for breast cancer.....	311
<i>Gene vaccine for breast cancer</i>	312
<i>Recombinant adenoviral ErbB-2/neu vaccine</i>	312
Gene Therapy for ovarian cancer	313
Gene therapy for malignant melanoma	313
<i>Immunogene therapy</i>	314
<i>Nonviral immunogene therapy for malignant melanoma</i>	315
<i>Oncogene targeted therapy</i>	315
<i>Targeted gene therapy for malignant melanoma</i>	315
Gene therapy of lung cancer.....	316
<i>Intravenous nanoparticle formulation for delivery of FUS1 gene</i>	316
<i>Aerosol gene delivery for lung cancer</i>	316
Gene therapy for cancer of prostate	316
<i>Experimental studies</i>	317
<i>Nanoparticle-based gene therapy for prostate cancer</i>	317
<i>Tumor suppressor gene therapy in prostate cancer</i>	317
<i>Vaccines for prostate cancer</i>	318
<i>Viral oncolysis for prostate cancer</i>	318
<i>Clinical trials of gene therapy for prostate cancer</i>	318
Gene therapy of head and neck cancer	319
<i>Adenoviral vector based P53 gene therapy</i>	319
<i>Gene therapy as adjunct to 5-FU for nasopharyngeal carcinoma</i>	319

Gene therapy of pancreatic tumors	319
<i>Pancreatic neuroendocrine tumors</i>	319
<i>Pancreatic ductal adenocarcinoma</i>	320
<i>Correction of altered genes</i>	321
<i>Targeted gene therapy</i>	321
<i>Targeting in pancreatic adenocarcinoma with cell surface antigens</i>	321
<i>Targeted Expression of BikDD gene</i>	322
<i>Viral oncolysis in pancreatic cancer</i>	322
<i>Concluding remarks on gene therapy of pancreatic cancer</i>	322
Gene therapy of renal cancer	322
<i>Viral oncolytic therapy for renal cancer</i>	322
Gene therapy of hematological malignancies	323
<i>Genetically engineered T lymphocytes</i>	323
Cancer gene therapy companies	323

6. Gene Therapy of Neurological Disorders 328

Indications 328

Gene transfer techniques for the nervous system 329

Methods of gene transfer to the nervous system	329
Ideal vector for gene therapy of neurological disorders	329
Promoters of gene transfer	329
Lentivirus-mediated gene transfer to the CNS	330
AAV vector mediated gene therapy for neurogenetic disorders	330
Gene transfer to the CNS using recombinant SV40-derived vectors	331
Routes of delivery of genes to the nervous system	331
<i>Direct injection into CNS</i>	331
<i>Introduction of the genes into cerebral circulation</i>	332
<i>Introduction of genes into cerebrospinal fluid</i>	332
<i>Intravenous administration of vectors</i>	333
Delivery of gene therapy to the peripheral nervous system	333
Cell-mediated gene therapy of neurological disorders	333
<i>Neuronal cells</i>	333
<i>Neural stem cells and progenitor cells</i>	333
<i>Astrocytes</i>	334
<i>Cerebral endothelial cells</i>	334
<i>Implantation of genetically modified encapsulated cells into the brain</i>	334
Gene transfer for neuromodulation	335

Monitoring of CNS gene therapy 335

Gene therapy of neurodegenerative disorders 335

Gene therapy for Parkinson disease	335
Rationale	336
<i>Techniques of gene therapy for PD</i>	337
<i>Augmenting CNS glucocerebrosidase activity</i>	340
<i>Delivery of neurotrophic factors by gene therapy</i>	340
<i>Delivery of parkin gene</i>	341
<i>Introduction of functional genes into the brain of patients with PD</i>	341
<i>Nanoparticle-based gene therapy for PD</i>	341
<i>Mitochondrial gene therapy for PD</i>	342
<i>RNAi approach to PD</i>	342
<i>Prospects of gene therapy for PD</i>	342
<i>Concluding remarks about gene therapy of PD</i>	343
<i>Companies developing gene therapy for PD</i>	343
Gene therapy for Alzheimer disease	344
<i>Rationale</i>	344
<i>NGF gene therapy for AD</i>	344
<i>FGF2 gene transfer in AD</i>	345
<i>Nepriylsin gene therapy</i>	346
<i>Targeting plasminogen activator inhibitor type-1 gene</i>	346
<i>Viral gene transfer of APP_{sw} for rescuing synaptic failure in AD</i>	347
<i>Gene vaccination</i>	347
<i>Combination of gene therapy with other treatments for AD</i>	347
Gene therapy of Huntington disease	347
<i>Encapsulated genetically engineered cellular implants</i>	348
<i>Viral vector mediated administration of neurotrophic factors</i>	348
<i>RNAi gene therapy</i>	348
Gene therapy of amyotrophic lateral sclerosis	348
<i>Rationale</i>	348
<i>Technique of gene therapy of ALS</i>	349
<i>Other approaches to gene therapy of ALS</i>	350

Gene therapy of cerebrovascular diseases 350

Preclinical research in gene therapy for cerebrovascular disease	350
--	-----

Animal models of stroke relevant to gene therapy	351
<i>Transgenic mice as models for stroke</i>	351
<i>Animal models for gene therapy of arteriovenous malformations</i>	351
Gene transfer to cerebral blood vessels	351
Gene therapy for vasospasm following subarachnoid hemorrhage	352
<i>NOS gene therapy for cerebral vasospasm</i>	353
Gene therapy for stroke.....	354
<i>Gene therapy for stroke using neurotrophic factors</i>	355
<i>Gene therapy of strokes with a genetic component</i>	355
<i>Gene therapy for intracranial aneurysms</i>	356
<i>RNAi-based gene silencing for neuroprotection in cerebral ischemia</i>	356
Concluding remarks about gene therapy for stroke.....	356
Gene therapy of injuries to the nervous system.....	356
Traumatic brain injury	356
Spinal cord injury.....	357
Peripheral nerve injuries	358
Gene therapy of epilepsy	358
Gene therapy for control of seizures	358
Gene therapy for neuroprotection in epilepsy	359
Gene therapy for genetic forms of epilepsy	360
Gene therapy for multiple sclerosis	360
Gene therapy for impairment of special senses	361
Gene therapy for hearing loss.....	361
Gene therapy for olfactory impairment	362
Gene therapy for relief of pain	362
Rationale of gene therapy for pain	362
Vectors for gene therapy of pain	362
Methods of gene delivery for pain	363
<i>Endogenous analgesic production for cranial neuralgias</i>	363
<i>Gene delivery by intrathecal route</i>	364
<i>Gene transfer for delivery of analgesics to the spinal nerve roots</i>	364
<i>Gene therapy of peripheral neuropathic pain</i>	365
<i>Gene transfer by injections into the brain substance</i>	366
Targets for gene therapy of pain	366
<i>Zinc finger DNA-binding protein therapeutic for chronic pain</i>	366
<i>Gene therapy for producing enkephalin to block pain signals</i>	367
<i>Targeting nuclear factor-κB</i>	367
<i>Gene therapy targeted to neuroimmune component of chronic pain</i>	368
Potential applications of gene therapy for management of pain.....	368
Concluding remarks on gene therapy for pain.....	369
Gene therapy for psychiatric disorders	370
Gene therapy for depression	370
Gene therapy for enhancing cognition after stress.....	370
Gene therapy against fear disorders.....	371
Companies involved in gene therapy of neurological disorders.....	371
7. Gene Therapy of Cardiovascular Disorders	372
Introduction	372
Techniques of gene transfer to the cardiovascular system	372
Direct plasmid injection into the myocardium	373
Catheter-based systems for vector delivery.....	373
Ultrasound microbubbles for cardiovascular gene delivery	374
Vectors for cardiovascular gene therapy	374
<i>AAV vectors for therapeutic delivery to the heart</i>	374
<i>Adenoviral vectors for cardiovascular diseases</i>	375
<i>Molecular cardiac surgery with recirculating delivery of AAV vectors</i>	375
<i>Plasmid DNA-based delivery in cardiovascular disorders</i>	375
Gene therapy for counteracting hypoxia in myocardial ischemia.....	375
Therapeutic angiogenesis vs vascular growth factor therapy.....	376
Gene painting for delivery of targeted gene therapy to the heart	376
Gene delivery to vascular endothelium	377
Targeted plasmid DNA delivery to the cardiovascular system with nanoparticles	377
Vascular stents for gene delivery	378
Gene therapy for genetic cardiovascular disorders	378
Catecholaminergic polymorphic ventricular tachycardia.....	378
Genetic disorders predisposing to atherosclerosis.....	379
Familial hypercholesterolemia.....	380
Apolipoprotein E deficiency.....	381
Hypertension.....	381
Genetic factors for myocardial infarction	382
Acquired cardiovascular diseases	383

Coronary artery disease with angina pectoris.....	383
<i>Ad5FGF-4</i>	383
Gene therapy for improving long-term CABG patency rates.....	384
Ischemic heart disease with myocardial infarction.....	384
<i>Gene therapy and angiogenesis in ischemic heart disease</i>	384
<i>Induction of angiogenesis in myocardium by HEXIM1 re-expression</i>	385
<i>Myocardial repair with IGF-1 therapy</i>	386
<i>Metalloproteinase-2 inhibitor gene therapy</i>	386
<i>miRNA gene therapy for ischemic heart disease</i>	387
Congestive heart failure.....	387
<i>Rationale of gene therapy in CHF</i>	387
<i>AAV-mediated gene transfer for CHF</i>	387
<i>AngioCell gene therapy for CHF</i>	388
<i>β-ARKct gene therapy</i>	389
<i>Elevating cardiac dATP by gene therapy to improve cardiac function</i>	389
<i>Elevating cardiac adenyl cylase type 6 to improve cardiac function</i>	390
<i>Intracoronary adenovirus-mediated gene therapy for CHF</i>	390
<i>nNOS gene transfer in CHF</i>	391
Cardiomyopathies.....	391
Cardiac conduction disturbances.....	391
<i>Gene transfer approaches for biological pacemakers</i>	392
<i>Genetically engineered biological pacemakers</i>	393
Gene therapy and heart transplantation.....	393
Hyperlipidemia and hypercholesterolemia.....	394
<i>Antisense approach to hypertriglyceridemia</i>	394
<i>Cholesterol reduction by genetic engineering of PCSK9 gene</i>	394
<i>Inactivating variants in ANGPTL4 for lowering circulating triglycerides</i>	394
Peripheral arterial disease.....	394
Incidence and clinical features.....	394
Current management.....	395
Gene therapy for peripheral arterial disease.....	395
<i>Angiogenesis by gene therapy</i>	395
<i>HIF-1α gene therapy for peripheral arterial disease</i>	396
<i>HGF gene therapy for peripheral arterial disease</i>	396
Prevention of restenosis after angioplasty.....	397
<i>Antisense approaches</i>	397
<i>Gene therapy to prevent restenosis after angioplasty</i>	397
<i>hTIMP-1 gene therapy to prevent intimal hyperplasia</i>	399
<i>miRNA-based gene therapy for restenosis</i>	399
<i>NOS gene therapy for restenosis</i>	399
<i>Techniques of gene therapy for restenosis</i>	400
Maintaining vascular patency after surgery.....	400
Companies involved in gene therapy of cardiovascular diseases.....	401
Future of gene therapy of cardiovascular disorders.....	402
8. Gene therapy of viral infections.....	403
Introduction.....	403
Acquired Immunodeficiency Syndrome (AIDS).....	403
Current management of AIDS.....	403
Gene therapy strategies in HIV/AIDS.....	404
<i>HIV/AIDS vaccines</i>	404
<i>Insertion of protective genes into target cells</i>	405
Cell/gene therapies for HIV/AIDS.....	406
<i>Transplantation of genetically modified T cells</i>	406
<i>Transplantation of genetically modified hematopoietic cells</i>	407
<i>Anti-HIV ribozyme delivered in hematopoietic progenitor cells</i>	408
Gene editing for HIV-1.....	408
Inhibition of HIV-1 replication by lentiviral vectors.....	408
<i>VRX496-T</i>	409
Intracellular immunization.....	409
Engineered cellular proteins such as soluble CD4s.....	410
Intracellular antibodies.....	410
Anti-rev single chain antibody fragment.....	410
Use of genes to chemosensitize HIV-1 infected cells.....	410
Autocrine interferon (INF)- β production by somatic cell gene therapy.....	411
Antisense approaches to AIDS.....	411
<i>RNA decoys</i>	411
<i>Antisense oligodeoxynucleotides</i>	411
<i>RNA decoys</i>	411
<i>Ribozymes</i>	412
RNAi applications in HIV/AIDS.....	412

<i>siRNA-directed inhibition of HIV-1 infection</i>	413
<i>Role of the nef gene during HIV-1 infection and RNAi</i>	413
<i>Bispecific siRNA constructs</i>	413
<i>Targeting CXCR4 with siRNAs</i>	414
<i>Targeting CCR5 with siRNAs</i>	414
Companies involved in developing gene therapy for HIV/AIDS	415
Conclusions regarding gene therapy of HIV/AIDS	415
Genetic vaccines for other viral infections	416
Cytomegalic virus infections	416
Viral hepatitis	417
<i>Vaccine for hepatitis B</i>	417
<i>Vaccine for hepatitis C</i>	417
<i>Gene therapy for hepatitis C</i>	417
Vaccine for herpes simplex virus	418
DNA vaccine against rabies	418
DNA vaccine for Ebola	419
Vaccines for avian influenza	419
<i>Future prospects of DNA vaccines for avian influenza</i>	420
<i>Human trial of a DNA vaccine for avian influenza</i>	420
Companies developing genetic vaccines for infections other than AIDS	421
9. Research, Development and Future of Gene Therapy	423
Basic research in gene therapy	423
R & D in gene therapy	423
Animal models of human diseases for gene therapy research	424
<i>Lentiviral transgenesis</i>	424
Financing research and development	424
Role of the NIH in gene therapy research	424
National Gene Vector Laboratories	424
Funding of gene therapy research in Europe	425
<i>Gene therapy funding in Horizon 2020 of European Commission</i>	425
Financing by the industry	426
Clinical trials in gene therapy	426
Clinical trials worldwide	426
<i>Clinical trials in cancer gene therapy</i>	427
<i>Trials of gene therapy for neurological disorders</i>	427
<i>Clinical trials for genetic disorders</i>	427
<i>Clinical trials in cardiovascular gene therapy</i>	427
<i>Clinical trials for infectious diseases</i>	427
<i>Gene therapy for other disorders</i>	427
Clinical trials in the US	427
Vectors used in gene therapy clinical trials	428
<i>Vector analytics for clinical trials using rAAV vectors</i>	429
Gene therapy in China	429
Future of gene therapy	430
How to improve gene therapy	430
International Gene Therapy Consortium	431
Future opportunities and challenges for gene therapy	432
Promising areas of application of gene therapy	433
<i>Neurological disorders</i>	433
<i>Gene therapy of cardiovascular disorders</i>	434
<i>Cancer gene therapy</i>	435
Personalized gene therapy	436
10. Regulatory, Safety, Ethical Patent Issues of Gene Therapy	437
Regulation of gene therapy in the United States	437
US Federal guidelines for research involving recombinant DNA molecules	437
Regulation of gene therapy in US	437
Implantation of genetically manipulated cells	437
<i>Modification of oocytes for use in IVF</i>	438
Clinical trials in gene therapy	438
Gene therapy INDs placed on hold by the FDA	438
FDA policy for advancing development of gene therapy	439
Do-it-yourself gene therapy	440
Regulation of gene therapy in Europe	441
European Union	441
Regulation of gene therapy in Germany	442
<i>Preclinical research</i>	442
<i>Clinical Trials</i>	442
Marketing authorization	443
Regulation of gene therapy in the United Kingdom	443

Regulation of gene therapy in France.....	444
Regulation of gene therapy in Italy	445
Regulation of gene therapy in the Netherlands.....	445
Gene therapy regulation in Switzerland.....	446
Regulation of gene therapy in Australia.....	446
Regulation of gene therapy in Japan.....	447
Regulation of gene therapy in China	448
Safety issues of gene transfer	449
Adverse effects of retroviral vectors	449
<i>Insertional mutagenesis</i>	449
Adverse effects of HSV vectors	450
<i>Neurotoxicity of HSV vectors</i>	450
<i>Hepatotoxicity of HSV-tk/ganciclovir approach</i>	450
Adverse effects of adenoviral vectors.....	450
<i>Inflammatory effects of adenoviruses in lungs</i>	450
<i>Inflammatory effects involving the liver</i>	451
<i>Induction of immune response by adenoviral vectors</i>	451
<i>Impairment of adrenocortical steroidogenesis</i>	452
<i>Adverse effects of AAV vectors</i>	452
Toxicity associated with cationic lipid-mediated gene transfer	452
Toxicity of lipopolysaccharides	453
Potential side effects of RNAi gene therapy.....	453
Role of molecular diagnostics in safety of gene therapy	453
Quality control of vectors.....	454
<i>Testing for retroviruses</i>	454
<i>Adenoviral vectors</i>	454
<i>Replication competent viruses</i>	454
Genetic characteristics of viral vectors	455
Concluding remarks about safety of viral vectors	455
Ethical aspects of gene therapy	455
The lay consumer's view of somatic gene therapy ethics	456
Ethical aspects of clinical trials.....	456
Regulatory and ethical issues for in utero gene therapy	457
Ethical aspects of germline gene therapy	457
Ethical aspects of mitochondrial replacement therapy	458
Ethical aspects of gene editing.....	458
<i>Ethical aspects of clinical trials of germline editing</i>	458
<i>Gene editing in the UK</i>	459
<i>Gene editing in the US</i>	460
<i>UNESCO's view on gene editing in humans</i>	461
Germline gene therapy for genetic enhancement	461
Athletic enhancement by genetic engineering	461
<i>Gene doping in sports</i>	462
<i>Gene transfer methods used for enhancing physical performance</i>	462
<i>Adverse effect of genetic engineering</i>	464
<i>Problems in detecting genetic manipulations in athletes</i>	464
<i>Ethical dilemma</i>	464
Gene therapy patents	465
CRISP/Cas9 patents	466
11. Markets for Gene Therapy	469
Introduction	469
Gene therapy markets in various regions of the world.....	469
Gene therapy markets according to therapeutic areas.....	470
Cancer gene therapy market	470
Markets for gene therapy of genetic disorders	471
Markets for DNA vaccines	471
DNA vaccines markets according to technologies	471
DNA vaccines markets according to therapeutic indications	472
DNA vaccines markets according to geographical areas	472
Competing treatments	473
Antisense.....	473
RNAi.....	473
Cell therapy	474
Strategies for developing gene therapy markets	474
<i>Collaboration with pharmaceutical companies</i>	474
<i>Collaboration with companies developing cell-based therapies</i>	474
<i>Collaboration with academic gene therapy centers</i>	474
<i>Developing safer and cost-effective gene medicines</i>	474
<i>Intellectual property and commercialization of gene therapy</i>	475
<i>Overcoming obstructions to the development of gene therapy</i>	475

Unmet needs in gene therapy	476
.....	476
Promises and challenges for the development of gene therapy	476
Development of gene therapy market in China	477
Challenges of developing gene therapy in the USA	477
Challenges of developing gene therapy in the European Union	477
12. References	479

Tables

Table 1-1: Landmarks in development of gene therapy.....	23
Table 2-1: Classification of methods of gene therapy.....	35
Table 2-2: A comparison of various physical methods of gene transfer	37
Table 2-3: Experimental applications of gene transfer by electroporation	39
Table 2-4: CRISPR vs other gene editing tools.....	50
Table 2-5: Companies developing CRISPR technology	59
Table 2-6: An overview of characteristics of commonly used viral vectors	65
Table 2-7: Companies using viral vectors.....	78
Table 2-8: Companies using nonviral vectors	97
Table 2-9: Target organs for nonviral gene therapy methods.	99
Table 2-10: Potential routes for administration of DNA	107
Table 2-11: Companies with gene delivery devices/ technologies.....	108
Table 2-12: Strategies for targeted gene therapy	109
Table 2-13: Animal experimental studies of in vivo gene delivery with polymer systems.....	111
Table 2-14: Approaches to controlling gene expression in gene therapy	111
Table 2-15: Companies with regulated/targeted gene therapy and special techniques	114
Table 2-16: Potential applications of human germline genome modification	115
Table 2-17: Applications of molecular diagnostics in gene therapy	130
Table 2-18: Advantages of gene therapy compared with protein therapy	132
Table 3-1: Experimental approaches to gene therapy of rheumatoid arthritis	137
Table 3-2: Gene therapy strategies for osteoarthritis.....	139
Table 3-3: Cell and gene therapy approaches for type 1 diabetes mellitus.....	145
Table 3-4: Indications for gastrointestinal gene therapy	152
Table 3-5: Hematological disorders that can be potentially treated by gene therapy.....	154
Table 3-6: Clinical trials of gene therapy for hemophilia A and B.....	155
Table 3-7: Companies involved in gene therapy of hematological disorders.....	166
Table 3-8: Techniques of gene transfer to the kidneys.....	171
Table 3-9: Gene therapy in animal experimental models of renal disease.....	174
Table 3-10: Applications of gene therapy in ophthalmological disorders	182
Table 3-11: Companies developing gene therapy for eye disorders	198
Table 3-12: Strategies for gene delivery to the lungs	202
Table 3-13: Companies developing gene therapy for pulmonary disorders	210
Table 4-1: Genetic disorders that are being investigated for gene therapy	222
Table 4-2: X-linked immunodeficiency disorders	224
Table 4-3: Examples of inherited metabolic disorders amenable to gene therapy	229
Table 4-4: Gene therapy approaches to Duchenne muscular dystrophy	248
Table 4-5: Companies involved in gene therapy of genetic/metabolic disorders	266
Table 5-1: Strategies for cancer gene therapy	268
Table 5-2: Cell-based gene therapy for cancer	273
Table 5-3: Companies with nucleic acids/genetically modified cell cancer vaccines	280
Table 5-4: Enzyme/prodrug combinations employed in suicide gene therapy.....	285
Table 5-5: Mutation compensation strategies used clinically	286
Table 5-6: Companies developing oncolytic viruses	301
Table 5-7: Strategies for gene therapy of malignant brain tumors.....	304
Table 5-8: Clinical trials of oncolytic virotherapy against glioblastoma multiforme.....	311
Table 5-9: Clinical trials of gene therapy in ovarian cancer.....	313
Table 5-10: Gene therapy for malignant melanoma.....	314
Table 5-11: Clinical trials of gene therapy for prostate cancer	318
Table 5-12: Companies involved in cancer gene therapy.....	323
Table 6-1: Example of potential indications for gene therapy of neurologic disorder	328
Table 6-2: Methods of gene transfer as applied to neurologic disorders	329
Table 6-3: Gene therapy techniques applicable to Parkinson disease	335
Table 6-4: Companies developing gene therapy for Parkinson's disease.....	343
Table 6-5: Gene transfer in animal models of carotid artery restenosis.....	352
Table 6-6: Gene therapy strategies for vasospasm.....	353
Table 6-7: Neuroprotective gene therapy in animal stroke models	354
Table 6-8: Experimental gene therapy approaches for relief of pain	363
Table 6-9: Companies involved in gene therapy of neurological disorders	371

Table 7-1: Cardiovascular disorders that are potential indications for gene therapy.....	372
Table 7-2: Catheter-based systems for vector delivery to the cardiovascular system.....	373
Table 7-3: Companies involved in gene therapy of cardiovascular diseases	401
Table 8-1: Strategies for gene therapy of AIDS	404
Table 8-2: Companies involved in developing gene therapy for HIV/AIDS	415
Table 8-3: Companies developing genetic vaccines for infections other than AIDS	421
Table 9-1: Geographical distribution of gene therapy clinical trials	426
Table 9-2: Opportunities and challenges for gene therapy and resources needed.....	432
Table 9-3: Potential applications of gene therapy in disorders of the nervous system	433
Table 10-1: Genes that may be used for performance enhancement	462
Table 11-1: Gene therapy market according to regions/countries – 2017 to 2027	469
Table 11-2: Gene therapy markets according to therapeutic areas – 2017 to 2027.....	470
Table 11-3: Cancer gene therapy market according to type of cancer - 2017 to 2027.....	470
Table 11-4: Gene therapy market for selected genetic disorders - 2017 to 2027.....	471
Table 11-5: DNA vaccines markets according to technologies - 2017 to 2027.....	472
Table 11-6: DNA vaccines markets according to therapeutic indications - 2017 to 2027.....	472
Table 11-7: DNA vaccines markets according to geographical areas - 2017 to 2027.....	472

Figures

Figure 1-1: Relation of gene therapy to other biotechnologies	26
Figure 1-2: Relationship of DNA, RNA and protein in the cell	30
Figure 2-1: Ex vivo and in vivo techniques of gene therapy.....	36
Figure 2-2: Structure of the Helios gene gun.....	42
Figure 2-3: A scheme of CRISPR/Cas9 gene editing	48
Figure 2-4: Use of CRISPR-Cas9 for hereditary hearing loss	57
Figure 2-5: Gene editing vs suppression of gene expression.....	61
Figure 2-6: Categories of rAAV-based gene therapy strategies	68
Figure 2-7: Bacteria plus nanoparticles for drug delivery into cells	95
Figure 2-8: Schematic of suppression of gene expression by RNAi	127
Figure 3-1: Retina and routes of administration of gene therapy for retinal disorders	188
Figure 4-1: Targeted gene correction of α 1-antitrypsin deficiency by iPSCs	232
Figure 4-2: Application of CRISPR-Cas9 in a mouse model of DMD.....	255
Figure 4-3: Techniques for mitochondrial nuclear transfer.....	264
Figure 5-1: Chimeric antigen receptor (CAR)-T cells attacking tumor cells.....	291
Figure 5-2: Gene therapy approaches for pancreatic cancer	320
Figure 6-1: Effect of tyrosine hydroxylase gene delivery on dopamine levels	337
Figure 6-2: Role of cell and gene therapy in stroke according to pathology and stage.....	356
Figure 9-1: Product development cycle in gene therapy.....	423
Figure 9-2: Proportions of therapeutic areas in clinical trials of gene therapy in the US.....	428
Figure 9-3: Proportions of various vectors used in gene therapy trials	428
Figure 10-1: Evaluation system of gene therapy clinical studies in Japan	448
Figure 11-1: Unmet needs in gene therapy	476